Could a 12-Week pill cocktail replace 6 months of TB treatment?
NCT ID NCT05556746
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a 12-week combination of four drugs (bedaquiline, clofazimine, pyrazinamide, and delamanid) works better than the standard 26-week treatment for drug-susceptible tuberculosis. About 94 adults with TB will be randomly assigned to either the short regimen or standard care. The main goal is to see how quickly the new combo clears TB bacteria from sputum, and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bedaquiline, clofazimine, pyrazinamide, and delamanid
What this could lead to
If this works, it could point toward a much shorter, 12-week treatment for drug-susceptible tuberculosis, making it easier for patients to complete therapy.
What could go wrong
This is a small, early-phase trial with only 94 participants. The new regimen may not be as effective or safe as standard treatment, and results may not apply to all TB patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GHESKIO
Port-au-Prince, Haiti
-
University of Cape Town
Cape Town, South Africa